Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: In their evaluation of the cost-effectiveness
of treatment for chronic hepatitis C infection, Dr Salomon and colleagues1 pointed out that their findings are highly sensitive
to alternative assumptions of the effect of both chronic HCV infection and
treatment on quality of life.1 The importance
of quality-of-life parameters to their models is largely due to the small
proportion of their baseline cohort—40-year-old patients with chronic
HCV infection—that is estimated to progress to advanced liver disease-related
Dore GJ, Thein H. Cost-effectiveness of Treatment for Chronic Hepatitis C InfectionCost-effectiveness of Treatment for Chronic Hepatitis C Infection. JAMA. 2003;290(15):1993–1994. doi:10.1001/jama.290.15.1993-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: